Pages that link to "Q45077998"

The following pages link to Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. (Q45077998):

Displaying 25 items.

• Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4 (Q28552201) (← links)
• Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects (Q33155841) (← links)
• Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine (Q34000752) (← links)
• Clinical Implications of the Nelfinavir‐Proton Pump Inhibitor Drug Interaction in Patients with Human Immunodeficiency Virus (Q34966486) (← links)
• CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy (Q35057831) (← links)
• A review of nelfinavir for the treatment of HIV infection (Q36546278) (← links)
• Current clinical treatments of AIDS. (Q37034589) (← links)
• Cytochromes P450: a structure-based summary of biotransformations using representative substrates (Q37079954) (← links)
• Formed and preformed metabolites: facts and comparisons. (Q37277366) (← links)
• Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite (Q37471054) (← links)
• Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy (Q38750666) (← links)
• Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System. (Q38814591) (← links)
• Accessing Drug Metabolites via Transition-Metal Catalyzed C-H Oxidation: The Liver as Synthetic Inspiration. (Q38977018) (← links)
• The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir (Q42758383) (← links)
• Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir (Q42862277) (← links)
• Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play? (Q43158045) (← links)
• Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability. (Q43779543) (← links)
• The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1‐mediated GSH export from cultured brain astrocytes (Q44176745) (← links)
• Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study (Q46107330) (← links)
• Clinical risks of St John's Wort (Hypericum perforatum) co-administration (Q47774682) (← links)
• Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. (Q53581870) (← links)
• Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum (Q57787270) (← links)
• Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes (Q84445086) (← links)
• Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics (Q95651180) (← links)
• Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data? (Q97590552) (← links)